Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus BREATHTEK UBT FOR H PYLORI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus BREATHTEK UBT FOR H PYLORI.
AMINOHIPPURATE SODIUM vs BREATHTEK UBT FOR H-PYLORI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
BREATHTEK UBT is a 13C-urea breath test that detects Helicobacter pylori infection. The patient ingests 13C-labeled urea; if H. pylori is present, its urease enzyme hydrolyzes urea to 13CO2, which is absorbed and exhaled, allowing detection by mass spectrometry or infrared spectroscopy.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
75 mg of 13C-urea oral powder dissolved in 75 mL water, administered once after a baseline breath sample; a second breath sample is collected 30 minutes after dosing.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
13C-urea has a plasma half-life of approximately 0.5–1 hour. The 13CO2 exhaled peak occurs at 20–30 minutes, reflecting rapid urease hydrolysis. The terminal half-life is not clinically relevant as the breath test relies on early exhalation kinetics.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
BreathTek UBT (13C-urea) is metabolized by H. pylori urease to 13CO2, which is exhaled. Unmetabolized urea is renally excreted; renal elimination of unchanged 13C-urea accounts for approximately 20-30% of the administered dose, with the remainder exhaled as 13CO2 within 60 minutes. Fecal/biliary excretion is negligible.
Category C
Category C
Diagnostic Agent
Diagnostic Agent